AU2003215725A1 - Materials and methods relating to the treatment of lymphoma - Google Patents

Materials and methods relating to the treatment of lymphoma

Info

Publication number
AU2003215725A1
AU2003215725A1 AU2003215725A AU2003215725A AU2003215725A1 AU 2003215725 A1 AU2003215725 A1 AU 2003215725A1 AU 2003215725 A AU2003215725 A AU 2003215725A AU 2003215725 A AU2003215725 A AU 2003215725A AU 2003215725 A1 AU2003215725 A1 AU 2003215725A1
Authority
AU
Australia
Prior art keywords
lymphoma
treatment
materials
methods relating
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215725A
Inventor
Freda Stevenson
Delin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2003215725A1 publication Critical patent/AU2003215725A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
AU2003215725A 2002-03-07 2003-02-24 Materials and methods relating to the treatment of lymphoma Abandoned AU2003215725A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0205395A GB0205395D0 (en) 2002-03-07 2002-03-07 Materials and methods relating to the treatment of lymphoma
GB0205395.7 2002-03-07
PCT/GB2003/000783 WO2003074059A2 (en) 2002-03-07 2003-02-24 Materials and methods relating to the treatment of lymphoma

Publications (1)

Publication Number Publication Date
AU2003215725A1 true AU2003215725A1 (en) 2003-09-16

Family

ID=9932517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215725A Abandoned AU2003215725A1 (en) 2002-03-07 2003-02-24 Materials and methods relating to the treatment of lymphoma

Country Status (3)

Country Link
AU (1) AU2003215725A1 (en)
GB (1) GB0205395D0 (en)
WO (1) WO2003074059A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
WO2008053486A1 (en) * 2006-11-02 2008-05-08 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
US10159675B2 (en) * 2015-12-02 2018-12-25 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
WO2003074059A3 (en) 2004-01-08
WO2003074059A2 (en) 2003-09-12
GB0205395D0 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
AU2003224638A1 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003217870A1 (en) Pini-modulating compounds and methods of use thereof
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003241599A1 (en) Compositions and methods for the treatment of hemophilia a
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2003215244A1 (en) Complexes and methods of using same
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003282593A1 (en) Polyphenolamine composition and method of use
AU2003215725A1 (en) Materials and methods relating to the treatment of lymphoma
AU2003279800A1 (en) Sulfatases and methods of use thereof
AU2003242841A1 (en) Hydrolysis of silanes and surface treatment with the hydrolysis product
AU2003272400A1 (en) Syts as modifiers of the p21 pathway and methods of use
WO2005042707A9 (en) Taspasel 1 and methods of use
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003240446A1 (en) Use of mob-5 in pain
AU2003265263A1 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase